Triple
T19773765
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | respiratory syncytial virus |
E474952
|
entity |
| Predicate | hasProphylaxis |
P137290
|
FINISHED |
| Object | nirsevimab |
—
|
NE NERFINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: nirsevimab | Statement: [respiratory syncytial virus, hasProphylaxis, nirsevimab]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: nirsevimab Context triple: [respiratory syncytial virus, hasProphylaxis, nirsevimab]
-
A.
ansuvimab
Ansuvimab is a monoclonal antibody used as a therapeutic treatment for infection caused by Zaire ebolavirus (Ebola virus).
-
B.
odesivimab
Odesivimab is a monoclonal antibody used as part of an antibody cocktail therapy for the treatment of Ebola virus infection.
-
C.
Comirnaty
Comirnaty is the brand name of the Pfizer–BioNTech mRNA COVID-19 vaccine used worldwide for the prevention of coronavirus infection.
-
D.
Vaxzevria COVID-19 vaccine
Vaxzevria COVID-19 vaccine is a viral vector coronavirus vaccine created to prevent COVID-19 infection and severe disease in adults.
-
E.
Hemlibra
Hemlibra is a monoclonal antibody medication used to prevent or reduce bleeding episodes in people with hemophilia A, including those with factor VIII inhibitors.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: nirsevimab Target entity description: Nirsevimab is a long-acting monoclonal antibody used to prevent severe respiratory syncytial virus (RSV) infection in infants and young children.
-
A.
ansuvimab
Ansuvimab is a monoclonal antibody used as a therapeutic treatment for infection caused by Zaire ebolavirus (Ebola virus).
-
B.
odesivimab
Odesivimab is a monoclonal antibody used as part of an antibody cocktail therapy for the treatment of Ebola virus infection.
-
C.
Comirnaty
Comirnaty is the brand name of the Pfizer–BioNTech mRNA COVID-19 vaccine used worldwide for the prevention of coronavirus infection.
-
D.
Vaxzevria COVID-19 vaccine
Vaxzevria COVID-19 vaccine is a viral vector coronavirus vaccine created to prevent COVID-19 infection and severe disease in adults.
-
E.
Hemlibra
Hemlibra is a monoclonal antibody medication used to prevent or reduce bleeding episodes in people with hemophilia A, including those with factor VIII inhibitors.
- F. None of above. chosen
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d8e51a43a08190956bc6df13c91a77 |
completed | April 10, 2026, 11:55 a.m. |
| NER | Named-entity recognition | batch_69e6535e450c8190a2628245ae0d0bd3 |
completed | April 20, 2026, 4:25 p.m. |
Created at: April 10, 2026, 1:48 p.m.